Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Webcasts|September 2, 2020

Media Selection Made Easy: Selecting the Best Media for Your Aseptic Process Simulation

Media fill tests ensure the safe production of parenteral drugs. Learn factors to consider when selecting media for aseptic process simulations including US and European regulatory requirements and eser requirement specifications for equipment and instruments. Tuesday Sept. 29, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing until Sept. 29, 2021.

Register free: http://www.biopharminternational.com/bp_w/media_selection

Event Overview:

Product safety is vital. Aseptic processors perform aseptic processing simulations or media fill tests to ensure the production of parenteral drugs is safe.

In this webcast, our media fill experts will give an overview of what to consider when selecting media for aseptic process simulations, in particular:

  • Regulatory requirements in the United States and the European Union, including changes to GMP Annex 1
  • User requirement specification for equipment and instruments

Key Learning Objectives:

  • Understand what regulations say about media fill tests
  • Review real-world examples of problems that may occur with media fill tests
  • Recognize the key challenges of selecting the right media for media fill tests
  • Discuss solutions to overcome those challenges

Speakers: Adèle Gisselmann, Global Product Manager Environmental Monitoring, Merck KGaA, Darmstadt, Germany

Tim Cser, Senior Technology Specialist, MilliporeSigma

Time and Date: Tuesday Sept. 29, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

On demand available after final airing until Sept. 29, 2021.

Sponsor: MilliporeSigma (the life science business of Merck KGaA, Darmstadt, Germany)

Register free: http://www.biopharminternational.com/bp_w/media_selection


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.